TORONTO, Sept. 20 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD - News; Amex: PME - News) today announced that it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second-generation spectrometer, or color reader, for the PREVU(x) Point of Care (POC) Skin Sterol Test, the Company’s commercially available test to assess risk of heart disease.
